Article
Population-based type-specific prevalence of high-risk human papillomavirus infection in Estonia.
BMC infectious diseases - 11 Mar 2010
Uusküla Anneli, Kals Mart, Kosenkranius Liina, McNutt Louise-Anne, DeHovitz J Jack
Abstract excerpt
BACKGROUND: Effective prophylactic vaccines are available against human papillomavirus (HPV) types 6, 11, 16, and 18 which are licensed for routine use among young women. Monitoring is needed to demonstrate protection against cervical cancer, to verify duration of protection, and assess replacement frequency of non-vaccine types among vaccinated cohorts. METHODS: Data from a population-based study were used to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
